Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000189951 | SCV000243619 | likely benign | not specified | 2014-01-20 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Labcorp Genetics |
RCV000696799 | SCV000825378 | benign | Tuberous sclerosis 2 | 2025-01-20 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000696799 | SCV002040298 | likely benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002345683 | SCV002643425 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-03-03 | criteria provided, single submitter | clinical testing | The p.I1797L variant (also known as c.5389A>C), located in coding exon 41 of the TSC2 gene, results from an A to C substitution at nucleotide position 5389. The isoleucine at codon 1797 is replaced by leucine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Baylor Genetics | RCV004567389 | SCV005054461 | uncertain significance | Isolated focal cortical dysplasia type II | 2024-02-14 | criteria provided, single submitter | clinical testing |